A Safety, Tolerability, PK, and PD Study of Once Weekly ISIS-FGFR4RX SC in Obese Patients

Inclusion Criteria

• •1. Must have given written informed consent (signed and dated) and any authorizations required by local law and be able to comply with all study requirements
• •2. Male or female patients between the age of 18-65 years, inclusive
• •* Females: Must be post-menopausal (defined as 12 months of spontaneous amenorrhea in females \> 55 years of age or, in females ≤ 55 years, 12 months of spontaneous amenorrhea without an alternative medical cause and FSH levels in the postmenopausal range for the laboratory involved)
• •* Males: Surgically sterile, abstinent or if engaged in sexual relations with women of childbearing potential, patient is utilizing an acceptable contraceptive method during and for 5 months after the last dose of ISIS 463588 or placebo (Study Drug)
• •3. Body Mass Index (BMI) between 30.0 and 40.0 kg/m2, inclusive
• •4. Patients who are willing to comply with all scheduled visits, treatment plans, laboratory tests and other study procedures
• •5. Agree to abstain from alcoholic beverages for at least 48 hours prior to clinic visits
• •6. Agree to maintain current diet and exercise regimen from Screening until End-of-Study